Tiny trial tests smarter chemo delivery in head and neck cancer
NCT ID NCT06338657
First seen Nov 01, 2025 · Last updated Jun 11, 2026 · Updated 33 times
Summary
This very early study looked at how a new version of the chemotherapy drug paclitaxel (called FID-007) affects immune cells around head and neck tumors. The drug is wrapped in a special polymer to help it reach deeper into tumors while sparing healthy cells. Only 1 person enrolled before the study was stopped, so no clear conclusions can be drawn.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Los Angeles General Medical Center
Los Angeles, California, 90033, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.